Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of evolocumab in hypercholesterolemia
2011-001915-29Phase 2Completed
- Sponsor
- Amgen
- Start
- Sep 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of evolocumab in hypercholesterolemia (2 arms), sponsored by Amgen. Primary endpoint: Subject incidence of adverse events. Started Sep 2011; status: completed.
02
Drugs
evolocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on 2011-001915-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001915-29.